Deletion of the vaccinia virus F13L gene results in a highly attenuated virus that mounts a protective immune response against subsequent vaccinia virus challenge

Antiviral Research

Volumn 93, Issue 1, 2012, Pages 160-166

  Vliegen, Inge ^a   Yang, Guang ^b   Hruby, Dennis ^b   Jordan, Robert ^b   Neyts, Johan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b SIGA Technologies Incorporated   (United States)

Author keywords

F13L; Mouse; Smallpox; Vaccination; Vaccinia

Indexed keywords

TECOVIRIMAT; UNCLASSIFIED DRUG; VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN; VIRUS PROTEIN F13L;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; INOCULATION; MOUSE; NONHUMAN; POXVIRUS INFECTION; PRIORITY JOURNAL; SCID MOUSE; VACCINE PRODUCTION; VACCINIA VIRUS; VIRUS ATTENUATION; VIRUS MUTATION; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; CELL LINE; GENE DELETION; MEMBRANE PROTEINS; MICE; MICE, NUDE; MICE, SCID; SMALLPOX VACCINE; VACCINES, ATTENUATED; VACCINIA; VACCINIA VIRUS; VIRAL ENVELOPE PROTEINS;

MUS; POXVIRIDAE; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 84355162303     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.11.010     Document Type: Article

References (36)

1. Blasco R., Moss B. Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein. J. Virol. 1991, 65:5910-5920.
2. Blasco R., Moss B. Role of cell-associated enveloped vaccinia virus in cell-to-cell virus spread. J. Virol. 1992, 66:4170-4179.
3. Borrego B., Lorenzo M.M., Blasco R. Complementation of P37 (F13L gene) knock-out in vaccinia virus by a cell line expressing the gene constitutively. J. Gen. Virol. 1999, 80:425-432.
4. Boulter E.A., Appleyard G. Differences between extracellular and intracellular forms of poxvirus and their implications. Prog. Med. Virol. 1973, 16:86-108.
5. Bray M. Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antiviral Res. 2003, 58:101-114.
6. Duraffour S., Vigne S., Vermeire K., Garcel A., Vanstreels E., Daelemans D., Yang G., Jordan R., Hruby D.E., Crance J.M., Garin D., Andrei G., Snoeck R. Specific targeting of the F13L protein by ST-246 affects orthopoxvirus production differently. Antivirus Ther. 2008, 13:977-990.
7. Esteban D.J., Buller R.M. Ectromelia virus: the causative agent of mousepox. J Gen. Virol. 2005, 86:2645-2659.
8. Evans D.H., Stuart D., McFadden G. High levels of genetic recombination among cotransfected plasmid DNAs in poxvirus-infected mammalian cells. J. Virol. 1988, 62:367-375.
9. Fenner F. Genetic studies with mammalian poxviruses. II. Recombination between two strains of vaccinia virus in single HeLa cells. Virology 1959, 8:499-507.
10. Fenner F., Henderson D.A., Arita I., Jezek Z., Ladnyi I.D. Smallpox and its eradication 1988, World Health Organization, Geneva, Switzerland.
11. Geddes A.M. The history of smallpox. Clin. Dermatol. 2006, 24:152-157.
12. Grosenbach D.W., Hruby D.E. Analysis of a vaccinia virus mutant expressing a nonpalmitylated form of p37, a mediator of virion envelopment. J. Virol. 1998, 72:5108-5120.
13. Grosenbach D.W., Jordan R., Hruby D.E. Development of the small-molecule antiviral ST-246 as a smallpox therapeutic. Future Virol. 2011, 6:653-671.
14. Gurt I., Abdalrhman I., Katz E. Pathogenicity and immunogenicity in mice of vaccinia viruses mutated in the viral envelope proteins A33R and B5R. Antiviral Res. 2006, 69:158-164.
15. Honeychurch K.M., Yang G., Jordan R., Hruby D.E. The vaccinia virus F13L YPPL motif is required for efficient release of extracellular enveloped virus. J. Virol. 2007, 81:7310-7315.
16. Hostetler K.Y. Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate. Viruses 2010, 2:2213-2225.
17. Hruby D.E., Guarino L.A., Kates J.R. Vaccinia virus replication. I. Requirement for the host-cell nucleus. J. Virol. 1979, 29:705-715.
18. Husain M., Moss B. Vaccinia virus F13L protein with a conserved phospholipase catalytic motif induces colocalization of the B5R envelope glycoprotein in post-Golgi vesicles. J. Virol. 2001, 75:7528-7542.
19. Husain M., Moss B. Similarities in the induction of post-Golgi vesicles by the vaccinia virus F13L protein and phospholipase D. J. Virol. 2002, 76:7777-7789.
20. Jacobs B.L., Langland J.O., Kibler K.V., Denzler K.L., White S.D., Holechek S.A., Wong S., Huynh T., Baskin C.R. Vaccinia virus vaccines: past, present and future. Antiviral Res. 2009, 84:1-13.
21. Jentarra G.M., Heck M.C., Youn J.W., Kibler K., Langland J.O., Baskin C.R., Ananieva O., Chang Y., Jacobs B.L. Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination. Vaccine 2008, 26:2860-2872.
22. Jordan R., Tien D., Bolken T.C., Jones K.F., Tyavanagimatt S.R., Strasser J., Frimm A., Corrado M.L., Strome P.G., Hruby D.E. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob. Agents Chemother. 2008, 52:1721-1727.
23. Katz E., Ward B.M., Weisberg A.S., Moss B. Mutations in the vaccinia virus A33R and B5R envelope proteins that enhance release of extracellular virions and eliminate formation of actin-containing microvilli without preventing tyrosine phosphorylation of the A36R protein. J. Virol. 2003, 77:12266-12275.
24. Katz E., Wolffe E., Moss B. Identification of second-site mutations that enhance release and spread of vaccinia virus. J. Virol. 2002, 76:11637-11644.
25. Lane J.M., Goldstein J. Adverse events occurring after smallpox vaccination. Semin. Pediatr. Infect. Dis. 2003, 14:189-195.
26. Moss B. Poxviridae and their replication. Fields Virology 2001, Lippincott Williams and Wilkins, Philadelphia, pp. 2849-2883. 4th. D.M. Knipe, P.M. Howley (Eds.).
27. Neyts J., Leyssen P., Verbeken E., De Clercq E. Efficacy of cidofovir in a murine model of disseminated progressive vaccinia. Antimicrob. Agents Chemother. 2004, 48:2267-2273.
28. Payne L.G. Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J. Gen. Virol. 1980, 50:89-100.
29. Roper R.L., Wolffe E.J., Weisberg A., Moss B. The envelope protein encoded by the A33R gene is required for formation of actin-containing microvilli and efficient cell-to-cell spread of vaccinia virus. J. Virol. 1998, 72:4192-4204.
30. Sánchez-Puig J.M., Blasco R. Isolation of vaccinia MVA recombinants using the viral F13L gene as the selective marker. Biotechniques 2005, 39:665-666.
31. Vijaysri S., Jentarra G., Heck M.C., Mercer A.A., McInnes C.J., Jacobs B.L. Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: intra-nasal vaccination. Vaccine 2008, 26:664-676.
32. Wolffe E.J., Katz E., Weisberg A., Moss B. The A34R glycoprotein gene is required for induction of specialized actin-containing microvilli and efficient cell-to-cell transmission of vaccinia virus. J. Virol. 1997, 71:3904-3915.
33. Wolffe E.J., Weisberg A.S., Moss B. Role for the vaccinia virus A36R outer envelope protein in the formation of virus-tipped actin-containing microvilli and cell-to-cell virus spread. Virology 1998, 244:20-26.
34. Xiao Y., Isaacs S.N. Therapeutic vaccines and antibodies for treatment of orthopoxvirus infections. Viruses 2010, 2:2381-2403.
35. Yang G., Pevear D.C., Davies M.H., Collett M.S., Bailey T., Rippen S., Barone L., Burns C., Rhodes G., Tohan S., Huggins J.W., Baker R.O., Buller R.L., Touchette E., Waller K., Schriewer J., Neyts J., De Clercq E., Jones K., Hruby D., Jordan R. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 2005, 79:13139-13149.
36. Yao X.D., Evans D.H. High-frequency genetic recombination and reactivation of orthopoxviruses from DNA fragments transfected into leporipoxvirus-infected cells. J. Virol. 2003, 77:7281-7290.